Swiss Life Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Swiss Life Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-43,319	Closed	-$5.01M	–	664
2023 Q3	$5.01M	Sell	43,319 -18,256	-30%	-$1.96M	0.08%	288
2023 Q2	$6.33M	Sell	61,575 -3,060	-5%	-$323K	0.09%	259
2023 Q1	$7.05M	Buy	64,635 +54,900	+564%	+$6.07M	0.11%	244
2022 Q4	$1.11M	Buy	9,735 +4,601	+90%	+$382K	0.02%	486
2022 Q3	$318K	Sell	5,134 -101	-2%	-$7.06K	0.01%	549
2022 Q2	$418K	Buy	5,235 +2	+0%	+$189	0.01%	541
2022 Q1	$551K	Hold	5,233	–	–	0.01%	511
2021 Q4	$564K	Hold	5,233	–	–	0.01%	499
2021 Q3	$573K	Buy	+5,233	New	+$543K	0.01%	495

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Swiss Life Asset Management's HZNP Position: Q4 2023 in Review

Swiss Life Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 43,319 shares — an estimated $5.01M sold.

Swiss Life Asset Management first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $7.05M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Swiss Life Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Swiss Life Asset Management sold 43,319 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $5.01M.
Swiss Life Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
Swiss Life Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.05M in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Swiss Life Asset Management's 13F filing for Q4 2023, filed 9 Dec 2025.